Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.75 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.75 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | TEC | P42680 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20998672 | 1.00 | BTK (0.75) | BTKCYP2C8KCNH2EGFRTEC | |
| SCHEMBL20998573 | 1.00 | BTK (0.75) | BTKCYP2C8KCNH2EGFRTEC | |
| SCHEMBL16676816 | 1.00 | BTK (0.75) | BTKCYP2C8KCNH2EGFRTEC | |
| SCHEMBL16676786 | 1.00 | BTK (0.75) | BTKCYP2C8KCNH2EGFRTEC | |
| SCHEMBL18044989 | 0.86 | BTK (1.00) | BTKCYP2C8KCNH2EGFRTEC | |
| SCHEMBL18044999 | 0.86 | BTK (1.00) | BTKCYP2C8KCNH2EGFRTEC | |
| SCHEMBL16671014 | 0.86 | BTK (1.00) | BTKCYP2C8KCNH2EGFRTEC | |
| SCHEMBL20998600 | 0.85 | BTK (0.57) | BTKCYP2C8KCNH2EGFRTEC | |
| SCHEMBL16676735 | 0.85 | BTK (0.57) | BTKCYP2C8KCNH2EGFRTEC | |
| SCHEMBL16676655 | 0.85 | BTK (0.55) | BTKCYP2C8KCNH2EGFRTEC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LCK | BTK 1/4885CYP2C8 1877/4885KCNH2 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.